Deferred hormone treatment in prostate cancer
Hall, R.R.
Progress in Clinical and Biological Research 243b: 439-440
1987
ISSN/ISBN: 0361-7742 PMID: 3659036 Document Number: 296008
Document emailed within 1 workday
Related Documents
Arena, F. 2008: Dutasteride in the treatment of hormone refractory prostate cancer Minerva Urologica e Nefrologica 60(2): 71-76St-Arnaud, R.; Lachance, R.; Dupont, A.; Labrie, F. 1986: Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate Clinical and Investigative Medicine. Medecine Clinique et Experimentale 9(4): 215-221
Ross, R.W.; Kantoff, P.W. 2007: Hormone-refractory prostate cancer: choosing the appropriate treatment option Oncology 21(2): 185-193; Discussion 194: 199-200
Shimizu, T.; Shibata, Y.; Uchida, T.; Satoh, J. 1993: Severe flare-up in a prostate cancer patient treated with luteinizing hormone-releasing hormone analogue depot Hinyokika Kiyo. Acta Urologica Japonica 39(10): 953-955
Labrie, F.; Dupont, A.; Bélanger, A.; Lacourcière, Y.; Monfette, J.E.; Monfette, G. 1986: Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer Annales d'Urologie 20(2): 98-106
Sinibaldi, V.J.; Carducci, M.; Laufer, M.; Eisenberger, M. 1999: Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer Seminars in Oncology 26(5 Suppl 17: 45-48
Ngo, L.S.M.; Yeo, A.; Wong, A.S.C.; Tay, M.Hiang. 2007: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Annals of the Academy of Medicine Singapore 36(10): 811-814
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Dondi, D.; Limonta, P.; Moretti, R.M.; Marelli, M.M.; Garattini, E.; Motta, M. 1994: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop Cancer Research 54(15): 4091-4095
Kraljić, I.; Tarle, M. 1987: Evaluation of endocrine therapy of prostate cancer by assessing tumor markers and hormone parameters. Hormonal "cross-over" treatment of false endocrine independent tumors Progress in Clinical and Biological Research 243b: 521-525
Suzuki, H.; Ito, H. 2002: Hormone dependency of prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 11): 59-64
Gibbons, R.P. 1989: Management of hormone-resistant prostate cancer Progress in Clinical and Biological Research 303: 337-345
Roth, B.J. 1996: New therapeutic agents for hormone-refractory prostate cancer Seminars in Oncology 23(6 Suppl 14: 49-55
Arai, Y.; Ogawa, O. 2019: Hormone Therapy and Castration Resistance of Prostate Cancer Canadian Journal of Urology 26(2): 9686
Roznovanu, S.L.ăc.ăm.; Amălinci, C.; Rădulescu, D.ţa. 2005: Molecular mechanisms in hormone-resistant prostate cancer Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 109(3): 577-583
Wilkes, G.M. 2010: Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer Oncology 24(10 Suppl): 46-48
Vorob'ev, N.A.; Nosov, A.K.; Vorob'ev, A.V.; Moiseenko, V.M. 2010: New perspectives in the drug therapy of hormone-resistant prostate cancer Voprosy Onkologii 56(6): 645-653
McCormick, D.L.; Rao, K.V. 1999: Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat European Urology 35(5-6): 464-467
Uekado, Y.; Hirano, A.; Inagaki, T.; Hiroi, A.; Watanabe, T. 1995: Combined hormone and chemotherapy for the patients with advanced prostate cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(8): 1041-1045
Horiguchi, A.; Hatakeyama, N.; Ikeuchi, K. 1999: Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 45(1): 31-35